The discovery of prion disease transmission in mammals, as well as a non-Mendelian type of inheritance in yeast, has led to the establishment of a new concept in biology, the prion hypothesis. The prion hypothesis postulates that an abnormal protein conformation propagates itself in an autocatalytic manner via recruitment of the normal isoform of the same protein as a substrate, and thereby acts either as a transmissible agent of disease (in mammals) or as a heritable determinant of phenotype (in yeast and fungus). Although reconstitution of fully infectious PrP Sc in vitro from synthetic components has not yet been achieved, numerous lines of evidence indicate that the prion protein is the major and essential component, if not the only one, of the prion infectious agent. This article summarizes our current knowledge about the chemical nature of the prion infectious agent, describes potential strategies and challenges related to the generation of prion infectivity de novo, proposes new hypotheses to explain the apparently low infectivity observed in the first synthetic mammalian prions, and describes plausible effects of chemical modifications on prion conversion.
More than 20 systemic and neurodegenerative maladies have been associated with the formation of ordered protein aggregates [1, 2] . A common feature among all "conformational" diseases is the conversion of a protein into highly ordered polymeric forms with cross β-sheet rich structures [3] . Among neurodegenerative disorders, however, the prion maladies were placed into a special category for the following reason. In addition to sporadic and familial forms, which are common for other neurodegenerative maladies, prion disease can also be infectious. Ironically, while prion researchers have been struggling to provide definite proof that the prion protein transmits the disease, other amyloidogenic proteins have been shown to be competent in transmitting certain neurodegenerative or systemic diseases in a prion-like manner [4] [5] [6] .
Biochemical nature of prion infectivity
The prion hypothesis states that the infectious agent of prion diseases is an abnormally folded isoform of the prion protein (PrP Sc ) that replicates its abnormal conformation [7, 8] . Because reconstitution of an efficient in vitro replication system using purified or synthetic components has not yet been achieved, substantial effort has been spent on identifying possible cellular cofactors that might be involved in prion conversion. It is still not clear whether any other cellular components are essential for prion replication and what role they may play. Hypothetically, these cellular components could be divided into two large categories: (i) co-factors that are important for stabilizing PrP Sc structure and, therefore, are a constituent part of PrP Sc ; and/or (ii) co-factors that are required for conversion from PrP With respect to the first group, polysaccharides that consist of an α-linked polyglucose have been shown to be permanent components of prion rods purified from scrapie brains [9, 10] . Approximately 5-15% of PrP Sc is composed of polysaccharides, which are believed to form a structural scaffold. This scaffold should have a significant impact on the accessibility of PrP Sc to proteolytic digestion and its half-life in a cell [9] ; it might also impact strain diversity. In addition to polysaccharides, small amounts of sphingolipids and cholesterol were found in purified preparations of prion rods, which is not surprising considering that lipids represent the cellular environment for prion conversion [11] .
After nearly two decades of searching, the attempts to identify nucleic acids as constituent components that are either essential for prion infectivity or specify strain-dependent properties have not been successful [12, 13] . While not essential for prion infectivity, nucleic acids might play some role in a complex process of prion conversion. Recent studies showed that antibody to DNA immunocaptured PrP Sc in brain homogenates, suggesting that PrP Sc might have high affinity for binding to nucleic acids [14] . The functional role of the PrP Sc -DNA complex needs to be clarified in future studies, as it remains uncertain whether this complex is formed in vivo, or is only present in homogenized tissues. Another study that exploited an in vitro conversion assay suggested that RNA molecules might be involved in facilitating prion replication [15] . Considering that RNAs were supplied at 100-1000-fold excess over the amount of PrP Sc to the conversion reactions, and that the stimulating effect of RNAs was shown to be sequence independent [16] , it is unlikely that RNAs serve as a catalyst of prion replication. The stimulating effects of RNA are more related to its polyanionic nature. Other classes of polyanions including sulfated polysaccharides were also found to stimulate prion conversion in a cell-free system [17] . Polyanions may provide a frame for aligning PrP C and PrP Sc molecules in a mutually favorable orientation. To date, the search for cellular cofactors that might be involved in prion replication is still going on.
Two strategies for de novo generation of prion infectivity in vitro
There are many technical challenges related to the generation of prion infectivity in vitro. Despite substantial conformational differences between PrP C and PrP Sc (PrP C is a PK-sensitive α-helical monomer, whereas PrP Sc is an assembled multimer characterized by enhanced resistance to PK-digestion and an increased amount of β-structure [18, 19] ), it is still unclear which physical property can be used as a valid probe for monitoring the formation of PrP Sc de novo in a cell-free system. Several recent studies have shown that the correlation between PK-resistance and prion infectivity that appeared to be well established in older studies is, in fact, not absolute [20] [21] [22] [23] . It is well known that acquiring a β-sheet rich conformation by PrP molecules or aggregation into insoluble fibrillar states are also not exclusively associated with the generation of prion infectivity [24, 25] . The fact that PrP Sc is intrinsically polymorphic and heterogeneous raises an additional skepticism as to whether any single physical property could be exploited as an in vitro marker of infectivity. It will be beneficial if future work determines whether a combination of physical properties such as a unique pattern of surfaceexposed epitopes distinguishes the infectious subpopulation of PrP from the broad range of abnormally folded non-infectious PrP states.
In an attempt to generate the infectious PrP forms, two different strategies have been pursued: (i) PrP Sc -dependent conversion or amplification [26] [27] [28] , and (ii) conversion of PrP C or recombinant PrP (rPrP) in the absence of a PrP Sc template [24, 29, 30] . Because cell-free amplification of PrP Sc has been discussed in several other review articles [31] , here we will focus on the second approach.
3. In vitro conversion of recombinant PrP or PrP C in the absence of PrP
Sc
This approach has more parallels with the sporadic formation of prions, rather than with prion diseases acquired through transmission. In opposition to the amplification approach, where the physical properties of the newly generated PrP
Sc are expected to mimic that of PrP Sc seeds, the conversion reaction in the absence of PrP Sc seeds poses uncertainty regarding the conformation of the final products of the reaction. To monitor conversion, most researchers have followed an increase in the PK-resistance or β-sheet rich structures. It is not surprising that, in the absence of a PrP Sc template, the conversion of rPrP or PrP C produced a large diversity of abnormal β-sheet rich isoforms, which acquired some but not all the physical characteristics of PrP Sc [24, 25, [32] [33] [34] [35] [36] [37] [38] . Together, these studies illustrate the intrinsic propensity of the PrP molecule to adopt a diverse range of conformations depending on solvent conditions and cofactors supplemented in the conversion reactions.
Generation of amyloid fibrils
By analogy to the studies where the amyloid form was shown to be equivalent to a prion state for several yeast prion proteins [39] [40] [41] , converting rPrP into amyloid fibrils seemed to be one of the possible ways for de novo generation of mammalian prion infectivity in vitro. For the last few years several protocols for producing fibrils from rPrP or PrP C have been developed by different groups. In contrast to yeast prion proteins in which the amyloidogenic regions are natively unfolded, the PrP domain associated with mammalian prion infectivity is structured and thermodynamically stable [42] . Because chemical denaturants and elevated temperatures are the most common way of manipulating the dynamic balance between different unfolding intermediate states, it is not surprising that the first experimental protocols for producing amyloid fibrils from the structured C-terminal domain of α-rPrP (rPrP90-231) utilized partially denaturing conditions such as chemical denaturants [24, 25, 29, 38] or combinations of elevated temperature and high pressure [36] . Subsequently, Riesner and co-workers established an alternative conversion procedure, where amyloid fibrils were produced by incubating rPrP90-231 or PrP C in the presence of low concentrations of sodium dodecyl sulfate or in the presence of lipids [43, 44] . Under partially denaturing conditions, amyloid fibrils were produced from both oxidized [29, 38] and reduced forms of rPrP90-231 [24, 33] . Our recent studies demonstrated that the full-length rPrP also converts into the fibrillar form under partially denaturing solvent conditions [45] . The lag-phase for the polymerization kinetics was shorter for the full-length rPrP relative to that of rPrP90-231 [46, 47] , suggesting that the unstructured N-terminal region facilitated this process. The lagphase was also shown to be dependent on the procedure for preparation of rPrP stock solution even when the conversion reactions were carried out under identical partially denatured conditions, an observation that is not yet fully understood [48] .
Synthetic mammalian prions
The most stringent criteria for judging whether prion infectivity is generated in vitro de novo is a bioassay in animals. There have been no reports showing the production of infectious prions in vitro with an infectivity titer high enough to cause disease directly in wild type animals [43] . Our former studies demonstrated, however, that the transmissible form of prion disease could be induced in transgenic mice that expressed PrP89-231 at high levels (Tg 9949) by inoculation with amyloid fibrils generated in vitro from rPrP89-230 [29, 49] . These fibrils did not cause disease within 600 days when inoculated directly into wild type mice. However, after the first passage in Tg 9949, the synthetic prions could be transmitted to both Tg 9949 and to wild type animals in a second passage [49] . Similarly to the fibrils formed from rPrP89-230, a chemically synthesized 55-residue peptide (residues #90-145) harboring a P101L mutation and refolded in vitro into a β-conformation has also induced disease in transgenic mice that express PrP(P101L) [50] . Opposite to the Tg 9949 mice, however, the Tg PrP(P101L) mice were found to develop disease spontaneously even in the absence of synthetic peptide [51] . Tg 9949 mice did not develop any clinical signs of spontaneous disease, nor they produced transmissible scrapie upon aging. Furthermore, unique biochemical and neuropathological features indicated that a novel strain of TSE evolved in Tg 9949 mice inoculated with fibrils [52] . The diseaseassociated PrP conformer identified in Tg PrP(P101L) mice inoculated with the synthetic 55-residue peptide, however, was conformationally indistinguishable from those found in the same Tg mice that developed disease spontaneously [21] . Taken together these data argue, that the 55-residue peptide accelerated a slowly progressing, spontaneous form of the disease, while the fibrils of rPrP89-230 caused prion disease de novo.
The incubation times observed upon inoculation of fibrillar rPrP89-230 were much longer than those exhibited by most known PrP Sc strains. Considering that the length of incubation time is typically used as a measure of prion infectivity titer (in the assay that is referred to as the incubation time assay), a hasty conclusion has been made that synthetic prions exhibited a very low infectivity titer. While such conclusion would be valid if one is testing the infectivity of natural TSE strains that have been well adapted to a particular host, the attempts to fit the data from transmission of synthetic prions into simple equations does not appear to be well justified. Nevertheless, a number of questions have to be addressed. Why, despite high expression levels of PrP89-231 in Tg 9949, does long incubation time precede the progression of prion disease? In what aspect are amyloid fibrils produced from rPrP89-230 deficient as infectious agent? While searching for an explanation for the long incubation time, it is important to acknowledge that the natural strains of PrP Sc evolved through natural selection and evolution [53] . Natural TSE strains might appear as a result of selection and evolution of different conformational subtypes of PrP Sc of sporadic origin. Only those strains that show a very fast rate of replication and, correspondingly, shorter incubation times have a chance to 'survive' in the natural environment and are also preferred by many laboratory investigators. Moreover, most strains that are currently used in laboratories were passaged numerous times and are well adapted to a particular host. For instance, in 1977 Kimberlin and Walker described an experimental model of scrapie in hamsters in which the incubation period decreased progressively over the first 4 passages before becoming stable at the 5th and subsequent passes [54] . Therefore, the long incubation time observed in testing the in vitro-generated fibrils would not be surprising at all if one considers that no selective pressure was applied to the synthetic prions produced in a plastic tube. For the above reasons, the first synthetic prions may simply fall into a category of very slow propagating strains. One can argue, however, why then did the incubation time become much shorter in subsequent passages of synthetic prions? Here, we propose two hypotheses referred to as the 'maturation' and 'adaptation' hypotheses, each of which equally well reconcile this paradox. These hypotheses might guide future studies on production of the next generation of synthetic prions.
The 'maturation' hypothesis
This hypothesis speculates that the amyloid fibrils generated in vitro are not yet mature prions, but rather correspond to a semi-infectious (i.e. with low specific infectivity) metabolic intermediate referred to as PrP*, which is on the pathway to PrP Sc (Fig. 1a ) [55] . Our previous studies revealed that the amyloid fibrils are more PK-sensitive than 'classical' PrP Sc ; therefore, further conversion steps or cellular cofactors might be required for acquiring a proper PK-resistant conformation [55, 56] . Specifically, we identified three major PK-resistant fragments in the amyloid form. These fragments encompassed residues 138/141-230, 152/153-230, and 162-230; these fragments remained assembled in fibrillar structures after PKtreatment and maintained high β-sheet content with high seeding activity as determined in a cell-free conversion assay [55] . Remarkably, the 152/153-230 and 162-230 products of amyloid fibrils generated at high concentrations of PK were similar to the PK-resistant fragments found in patients with sporadic CJD [57] . Furthermore, PrP Sc exposed to partially denaturing conditions (2.5 M GdnHCl) displayed a similar PK-resistant core, where the C-terminal regions (residues ∼140-230) remained intact [58] . Therefore, the C-terminal PK-resistant fragments found in sporadic CJD and produced in vitro might be proteolytic products of PrP*, a metabolic intermediate or a byproduct of formation of 'classical' PrP Sc . If it is true, the long lag-phase observed in the first passage of amyloid fibrils simply reflects the additional incubation time required for conversion of PrP* into mature PrP Sc . It remains to be determined whether any molecules assist the maturation and production of infectious prions. In summary, the 'maturation' hypothesis assumes that the amyloid fibrils (or PrP*) and PrP
Sc have similar substructure, and that maturation may involve interaction with as yet unknown cellular co-factors that stabilize PK-sensitive regions of PrP*.
The 'adaptation' hypothesis
The 'adaptation' hypothesis postulates that the shortening of incubation times observed in the second passage of synthetic prions may be attributed to conformational adaptation to the host suggesting that an apparent transmission barrier precludes efficient propagation of the synthetic prions in the first passage (Fig. 1b) . A transmission barrier is typically observed when the sequence of PrP Sc in the inoculum does not match that of PrP C in the recipient animals [59] [60] [61] [62] . Besides the differences in the sequences of PrPs between recipient and donor species, other factors such as strain-specific conformational differences also contribute to the transmission barrier. Noteworthy, the complex behavior of transmission of different scrapie strains was described in 1960s and 70s, long before the prion-only concept of prion propagation was introduced. Pattison and Jones showed that passage of a scrapie strain which is well adapted to mouse through other species resulted in modification of strain properties [61] . In other studies, Kimberlin and Walker recognized that the 'adaptation' of scrapie strains transmitted from a donor to acceptor species may involve the selection of a single strain from a mixture and/or modification of strain properties [63] . Modification of strain properties could be temporal or permanent depending on transmission path in the subsequent passages [64] . Since then, different strains of prion disease have been found to have significantly different propensities to overcome the transmission barrier, presumably as a result of different conformations of PrP Sc [65, 66] . Furthermore, some but not all recipient species can propagate certain strains from donor species [62] .
Using animal models of prion transmission, an intimate link between the species barrier and the strain phenomenon has been well established in the last several years. The biophysical mechanism of this unique phenomenon and the folding rules that control the strain-specificity of the speciesbarrier have yet to be discovered. Fig. 2 illustrates a framework that provides some insight into the strainspecificity of the species barrier. This framework helps to explain on a very simplistic level why some strains from donor species can be transmitted to recipient species, while other strains cannot; and why some but not all recipient species can propagate certain strains from donor species. This model also predicts that an intermediate passage through a third species might be necessary for successful transmission of some strains from one species to other species.
What factors cause an artificial 'in vitro-in vivo' transmission barrier in propagation of synthetic prions? Because the sequence of rPrP89-230 in the amyloid fibrils was identical to that of endogenously expressed PrP C (mouse PrP89-230), it is likely that the apparent transmission barrier arises due to the unique conformational properties of the fibrils. Specifically, in contrast to the classical PrP Sc , the fibrils generated in vitro . As yet unidentified cellular cofactors may be required for maturation. (b) The 'adaptation' hypothesis postulates that efficient propagation of synthetic prions in the first passage is precluded due to an apparent transmission barrier. Transmission barriers arise because the subset of fibrillar conformers that are generated from rPrPs in vitro does not overlap with the subset of PrP Sc strains produces in vivo. The differences in the incubation time in the first and second passages of the synthetic prions are attributed to conformational adaptation.
were characterized by (i) the high proteolytic lability of residues 90-138 [55] , (ii) the lack of glycosylation and GPI anchor, and (iii) the unusually high conformational stability of the cross-β-sheet fibrillar core [55] . Each of these three factors individually or all together could contribute to the appearance of an artificial in vitro-in vivo transmission barrier and the necessity for conformational adaptation.
Resent studies, however, argued that the GPI anchor has minimal, if any, impact on prion infectivity. Removal of the GPI anchor from mature PrP Sc did not reduce prion infectivity [67] . Furthermore, anchorless PrP Sc generated in GPI-deficient mice in the form of amyloid fibrils was shown to be highly infectious [68] . While the GPI anchor seems to be unessential for acquiring an infectious conformation, the possible impact of glycosylation is less certain. For instance, in the absence of carbohydrates the steric constraints that might have been imposed on the packing of the polypeptide chain in the cross β-sheet fibrillar core in vivo is removed. Therefore, in the fibrillar state, carbohydrates-deficient PrP molecules may adopt a conformation different from the disease-specific conformations formed from PrP C in the cell. The unusually high conformational stability of the in vitro generated fibrils is another factor that is likely to contribute to the 'in vitro-in vivo' transmission barrier. The conformational stability of fibrils can be estimated from a solvent-induced denaturation experiment, from which the C 1/2 value is calculated (C 1/2 is the concentration of GdnHCl at which 50% of fibrils are folded and 50% are unfolded as estimated from the two-state folding model). Unexpectedly, consistent with synthetic mammalian prions, low infectivity of amyloid fibrils produced from yeast prions was linked to their high conformational stability. A possible relationship between the conformational stability and fibril infectivity represents an emerging concept in yeast and mammalian prions and, therefore, will be discussed in the next chapter.
Does conformational stability control the infectivity of amyloid fibrils?
Recent studies revealed a strong link between conformational stability and infectivity of amyloid fibrils formed by the yeast prion protein Sup35 [41] . The amyloid fibrils that displayed low conformational stability were found to exhibit a high efficiency of infection with the large majority of colonies showing a strong phenotype ('strong' strains) [41] . Vice versa, fibrils that had high conformational stability displayed low infectivity and produced 'weak' strains. In yeast prions, the weak strains are defined as those strains that disappear fast or that could be easily cured, whereas the strong strains are characterized by their ability to sustain fast growing colonies for a long period of time.
A similar correlation between conformational stability and infectivity was identified in our experiments with synthetic mammalian prions. In contrast to yeast prions, however, the apparent infectivity of mammalian prions is judged by the length of the incubation time, but not from the efficiency of infection. When tested in GdnHCl-induced denaturation experiments, the amyloid fibrils of rPrP 89-230 generated in vitro displayed an unusually high C 1/2 value of 4.1 M [55] . The same C 1/2 value was observed for MoSP1 (Mouse Synthetic Prion strain 1) formed in Tg9949 mice upon inoculation of fibrillar rPrP 89-230, when very long incubation time of 516 days was observed [49] . Therefore, the high C 1/2 value for MoSP1 correlated well with the unusually long incubation time; this C 1/2 value was substantially higher than those found for other prion strains. In GdnHCl-induced denaturation, most of the 'natural' prion strains exhibited C 1/2 values between 1 M and 2.5 M [69] . Remarkably, the second passage of MoSP1 resulted in substantial shortening of the incubation time from 516 days to only 258 days. Such dramatic change in the incubation time was accompanied by a substantial decrease in the conformational stability of MoSP1 as reflected by a change in the C 1/2 value from 4.2 M to 1.7 M GdnHCl (Fig. 3) . Both, the shortening of the incubation time and a decrease in conformational stability, are signs of the conformational adaptation of MoSP1, resulting in a C 1/2 and the length of the incubation time similar to that observed for 'natural' prion strains.
These studies suggest that the intrinsic infectivity of fibrils might be controlled, at least in part, by the conformational stability of the cross-β-sheet core (Fig. 3) . The molecular mechanism that accounts for the correlation between conformational stability and intrinsic infectivity has yet to be explored. Conformational stability is likely to be linked to the mechanical properties of fibrils such as their intrinsic fragility, (ii) The particular conformation occupied by newly generated PrP Sc within a given conformational space is specified by PrP Sc seeds or templates. (iii) Subsets of conformers (strains) formed by PrP's from different species may overlap suggesting that some PrP Sc strains are more universal and can be shared by two or more species, whereas other strains are more species-specific. For instance, strain n is shared by species A, B, and C, while strain m is shared by species A and C. Only those strains that occupy overlapping areas can be propagated by more than one species.
i.e. the ability of fibrils to fragment into shorter pieces. Because fragility controls the rate of multiplication of active centers in prion replication [47] , the conformational stability should have a direct impact on intrinsic infectivity. While shaking and sonication are known to fragment prion fibrils in vitro [28, 47] , the cellular mechanism responsible for PrP Sc fragmentation in vivo is unknown.
The new concept that the rate of prion replication and the length of the incubation time are, to a large extent, depends on the conformational stability of the cross-β-fibrillar core has direct implication for many issues in the prion field including the generation of prion infectivity in vitro. If this new concept is correct, the efficient replication of synthetic prions in vivo was precluded because of the high conformational stability of Mo rPrP 89-230 fibrils produced in vitro (Fig. 3) . From the perspective of a free energy landscape, conformational adaptation requires a walk 'uphill', from a thermodynamically most stable amyloid conformation toward a less stable but biologically more relevant form (Fig. 3) .
As a concluding note, it is important to mention that the 'maturation' and 'adaptation' hypothesis are different in one key aspect. The 'maturation' hypothesis postulates that amyloid fibrils or PrP* generated in vitro have a substructure very similar to that of PrP Sc , and that this substructure is largely preserved upon maturation of PrP* into PrP Sc . The 'adaptation' hypothesis, on the other hand, suggests that the amyloid fibrils are primitive surrogates of PrP Sc and that the substructure of amyloid fibrils may change dramatically in the course of adaptation. The 'maturation' and 'adaptation' hypotheses are not mutually exclusive of each other. Future studies should determine whether either of above hypotheses is correct. Fig. 3 . Schematic illustration of energy landscape of the prion conversion. The conformational space occupied by PrPSc strains (red dots) produced from PrP C in vivo is limited and does not overlap with the space occupied by amyloid fibrils (green dots) generated from non-glycosylated rPrP in vitro. Fibrils produced in vitro ('weak' strains) are conformationally more stable than PrP Sc ('strong' strains), therefore, conformational adaptation requires a walk 'up-hill'.
Chemical modifications
The effect of chemical modification on prion conversion has not been given full consideration in the past. Limitations in the sensitivity of techniques utilized for detecting protein modifications and difficulties in working with insoluble PrP Sc isolates account in part for gaps in our knowledge [70] .
Chemical modifications of the proteins are similar to point mutations; therefore, their effect on the protein secondary structure and susceptibility to conformational changes could be dramatic. While prion diseases are believed to result from conformational changes in prion protein, changes in primary structure such as those caused by chemical modifications may play an important role in individual susceptibility to the disease and the rate of disease progression.
The most common spontaneous chemical modifications to proteins are oxidative damage, side chain amide hydrolysis and reactions with electrophiles. Various enzymatic modifications are also present. Due to their longer lifetime in the cells, protein aggregates (such as PrP Sc ) often accumulate more chemical modifications compared to other cellular proteins. It us unclear, however, whether modifications occurred before or after conversion to PrP Sc and whether they have any effect on the conversion. Prion replication is a highly cooperative process, and even a small subpopulation of modified PrP C could have a substantial impact on kinetics and product distribution of this process [71] . While several types of chemical and enzymatic modifications have been detected in PrP Sc [72, 73] (methionine oxidation, aspartate deamination, AGE adducts, proline hydroxylation), the list is probably incomplete. Further studies employing newly developed sensitive techniques should be able to address the questions that have been difficult to study in the past. Here we will survey the most common types of spontaneous modification in PrP and other amyloidogenic proteins and their known effects on conversion into disease-related forms.
Oxidative damage
Oxidation of the proteins is a common process in biological systems [74] . While glutathione serves as a natural antioxidant in vivo, its levels decrease with age and protein oxidation becomes more prevalent. Methionines are considered the most reactive amino acids but oxidation can also impact histidines, tyrosines, tryptophans and other residues. Methionine is usually oxidized to the methionine sulfoxide [75] .
The reaction can be reversed by the methionine sulfoxide reductase, a common cellular enzyme. Oxidation of methionines can have a drastic effect on protein structure due to a much higher polarity and lower flexibility of methionine sulfoxide compared to the methionine side chain itself [76] .
Methionine oxidation was shown to inhibit fibrillation of several amyloidogenic proteins such as α-synuclein [77, 78] and Aβ [79, 80] . Oxidation of methionines in PrP C is a common process in vivo since PrP C is present in an environment rich with reactive oxygen species [81, 82] . Not surprisingly, oxidized methionines have been found in PrP Sc , although it is not clear whether the oxidation occurred during handling of the PrP Sc isolates [73] . Methionine residues in the central region of PrP (residues 90-140) are especially prone to oxidation [83] . Methionine oxidation interferes with fibril formation from the peptide corresponding to residues 106-126 of PrP [84] and from full-length rPrP [71] . Furthermore, oxidation of methionines in preformed rPrP fibrils was shown to inhibit conformational rearrangement of the region 90-140 into PrP Sc -like PK-resistant state [56, 71] . This inhibition can be attributed to perturbation of the structure of 90-140 region by methionine sulfoxides. Because some methionines in PrP occupy positions essential for species barrier and the number and location of methionines in PrP depend on the species [85] , oxidation of these residues could play a role in development or alteration of the species barrier for PrP Sc inter-species transmission.
In addition to methionines, tyrosines are also subject to oxidative modifications such as nitration and dimerization. Spontaneous or peroxidase-mediated nitration of tyrosine with peroxynitrite leads to 3-nitrotyrosine [86] .
This modification decreases the pK a of the tyrosyl hydroxyl group from 10.1 to 7.2 making a significant percentage of nitrotyrosines negatively charged at physiological pH. Low levels of nitrotyrosines were shown to promote fibril formation from α-synuclein [87] and tau protein [88] . Oxidative dimerization of tyrosines is usually caused by their reactions with reactive oxygen species, often metal-catalyzed [74] .
Nitrotyrosines or tyrosine dimers have not been detected in PrP C or PrP Sc but their presence at low levels cannot be ruled out. PrP Sc -dimers are often seen in SDS-PAGE performed under strongly reducing conditions. Whether these dimers appeared due to formation of intermolecular disulfide bonds or due to tyrosine dimerization remains uncertain. The effects of these modifications on other proteins suggest that they might promote PrP Sc formation.
Deamidation
Deamidation of the side chains of asparagines and glutamines is relatively common under physiological conditions [89] . This reaction proceeds via a complex mechanism, and both rate and product distribution is dependent on protein sequence and secondary structure.
Half-life of asparagines and glutamines can range from a few hours to months depending on the sequence. Deamidation converts neutral amino acids (Asn, Gln) to negatively charged ones. Like oxidation, this is a significant change in protein structure similar to point mutation and may influence protein fibril formation. Deamidated asparagines and glutamines have been found in paired helical filaments formed by the tau protein [90] . Deamidation of Asn107 has been observed in rPrP upon prolonged storage [91, 92] and in PrP Sc [93] . In rPrP this modification leads to increased protein aggregation in the presence of copper ions [91] . It is unclear whether low levels of this modification found in PrP Sc (0.5%) had any impact on PrP Sc formation [93] . Nonetheless, prion polymerization is a highly cooperative process, and Asn107 is located in the region of PrP C that is believed to be essential for acquiring an infectious conformation [94] [95] [96] .
Reactions with aldehydes
Reducing sugars (glucose, fructose) and sugar-derived aldehydes (methylglyoxal, glyoxal) can reversibly react with amino groups of the proteins (Lys, Arg, N-termini) to form Schiff base adducts. Slow rearrangement of these adducts can lead to more stable Amadori products and further to the heterogeneous set of adducts known as advanced glycation end-products (AGEs) [97, 98] .
Due to slow turnover of proteins within amyloid deposits it is not surprising that AGE adducts are present in many protein fibrils in vivo [98] [99] [100] . In addition to disruption of the protein structure, these modifications can also lead to protein crosslinking. Crosslinking by AGEs may have multiple effects including stabilization of aggregated forms and acceleration of polymerization [101] [102] [103] .
Similar to other protein deposits, prion plaques contain AGEs [104] , which are believed to be carboxymethyl adducts. These modifications have been localized to lysine (Lys 23, Lys 24, Lys 27) and arginine (Arg 37) residues in N-terminal region of PrP Sc [72] . Earlier sequencing studies have also suggested a modification at Arg 25 in both PrP C and PrP Sc [105] , although its nature was unclear at that time.
Highly reactive aldehydes (e.g. 4-hydroxy-2-nonenal and malondialdehyde) are also produced by lipid peroxidation [106] . Their adducts were found in deposits of serum amyloid A [107] and tau protein [108] . Effects of these aldehydes on the prion protein have not been investigated, but, considering that PrP C is bound to membranes in often highly oxidizing environments, modifications by lipid-derived aldehydes are likely to be present in PrP C and, possibly, in PrP Sc at low levels.
Enzymatic modifications
Proteins are subject to many enzymatic post-translational modifications. Small amounts of hydroxylation at Pro 44 were found in PrP Sc from the brains of infected mice [109] . This modification is likely a consequence of this region present in a polyproline II structure similar to collagen [110] since collagen-specific prolyl 4-hydroxylase modifies the proline residues in this conformation.
